Report Overview

Indian MRSA Infections Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen staphylococcus aureus. Methicillin-resistant Staphylococcus aureus (MRSA) can be divided into two types based on the mode of infection; hospital-associated MRSA infection (HA-MRSA) and community-associated MRSA infections (CA-MRSA). This infection is mainly associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection. Various antibacterial agents such as vancomycin, daptomycin, ceftaroline fosamil, tetracycline, clindamycine, and tedizolid phosphate are available in the market for treatment of infections associated with MRSA.



Market Drivers

Growing incidence of infections associated with Methicillin-resistant staphylococcus aureus (MRSA) pathogens is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant staphylococcus aureus (MRSA), which is expected to boost market growth.Lipopeptide segment accounts for the major market share owing to the novel antibiotic therapy introduced for MRSA. The therapy includes daptomycin, a lipopeptide class of drug and linezolid, an oxazolidinone class of antibiotics. The rapid implementation of therapy is expected to fuel the market growth. Furthermore, the glycopeptides and lipoglycopeptides segment is expected to show significant growth, owing to the increasing focus of manufacturers on the development of advanced drugs in this class.